The Motley Fool
04 Jul 2026, 13:44 UTC · 17w ago
Impact · against what's priced in
The article provides FY 2025 financial performance for IOVA and HTFL, showing strong top-line growth offset by significant operational losses. While the revenue trajectories are bullish, the persistent cash burn maintains a high risk profile for both growth-stage companies.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Iovance Biotherapeutics reported FY 2025 revenue of $263.5 million, representing a 60.6% year-over-year growth rate.
More positive than 92% of claims this week
Heartflow reported FY 2025 revenue of approximately $176 million, a 40% increase over the prior year.
Continue reading
5 related stories
FY 2025 revenue grew 60.6% to $263.5 million, though this scaling is accompanied by a $391 million net loss and negative free cash flow of $336.2 million.
Read from the article alone
No priced-in read yet
Revenue increased 40% to $176 million in FY 2025, though the company remains unprofitable with a net loss of $116.8 million and negative free cash flow of $59 million.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
Iovance Biotherapeutics recorded a net loss of roughly $391 million and negative free cash flow of $336.2 million for FY 2025.
So whatHigh burn rates and deep losses increase financial risk and the potential need for future dilutive capital raises.
More negative than 87% of claims this week
Heartflow reported a net loss of $116.8 million and negative free cash flow of $59.0 million for the year.
More negative than 79% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
Significant 60.6% revenue growth and successful commercial scaling of lead therapies, despite high net losses.
More positive than 59% of ticker scores this week
Strong top-line revenue growth of 40%, though offset by a net loss and negative free cash flow.
More positive than 45% of ticker scores this week
Mentioned as a partner in a critical license agreement supporting Iovance's pipeline.
More positive than 45% of ticker scores this week
Mentioned as a partner in a critical license agreement supporting Iovance's pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
7h ago
More positive than 34% of relationship scores this week
[mutual] Iovance maintains critical license agreements with Cellectis SA.
+96.8%
Price agrees with the score
$8.48 vs $4.31 close before publication (Jul 2) · not market-adjusted
IOVA chart →+111.1%
Price agrees with the score
$59.05 vs $27.97 close before publication (Jul 2) · not market-adjusted
HTFL chart →
